These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 34071152)
1. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy. Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand. Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185 [TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Huang X; Bennett M; Thorpe PE Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089 [TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346 [TBL] [Abstract][Full Text] [Related]
5. HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7. Cao L; Li Q; Tong Z; Xing Y; Xu K; Yijia Wang J; Li W; Zhao J; Zhao L; Hong Z Int J Pharm; 2020 Jan; 574():118939. PubMed ID: 31836485 [TBL] [Abstract][Full Text] [Related]
6. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. Michalska M; Schultze-Seemann S; Bogatyreva L; Hauschke D; Wetterauer U; Wolf P Oncotarget; 2016 Apr; 7(16):22531-42. PubMed ID: 26968813 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Wang X; Ma D; Olson WC; Heston WD Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220 [TBL] [Abstract][Full Text] [Related]
9. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196 [TBL] [Abstract][Full Text] [Related]
10. Michalska M; Schultze-Seemann S; Kuckuck I; Wolf P Anticancer Res; 2018 Jan; 38(1):61-69. PubMed ID: 29277757 [TBL] [Abstract][Full Text] [Related]
11. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319 [TBL] [Abstract][Full Text] [Related]
12. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth. Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065 [TBL] [Abstract][Full Text] [Related]
13. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Wolf P; Gierschner D; Bühler P; Wetterauer U; Elsässer-Beile U Cancer Immunol Immunother; 2006 Nov; 55(11):1367-73. PubMed ID: 16547705 [TBL] [Abstract][Full Text] [Related]
14. An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy. Zhang F; Shan L; Liu Y; Neville D; Woo JH; Chen Y; Korotcov A; Lin S; Huang S; Sridhar R; Liang W; Wang PC Adv Healthc Mater; 2013 May; 2(5):736-44. PubMed ID: 23184611 [TBL] [Abstract][Full Text] [Related]
15. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535 [TBL] [Abstract][Full Text] [Related]
16. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100 [TBL] [Abstract][Full Text] [Related]
17. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer. Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970 [TBL] [Abstract][Full Text] [Related]
18. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545 [TBL] [Abstract][Full Text] [Related]
19. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460 [TBL] [Abstract][Full Text] [Related]